Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report.

IF 3.9 The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-06 DOI:10.1080/09546634.2025.2462783

Zhuren Ruan, Chen Zhao, Longshan Li, Xianghui Li, Zhijian Yao, Gao Wei

{"title":"Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report.","authors":"Zhuren Ruan, Chen Zhao, Longshan Li, Xianghui Li, Zhijian Yao, Gao Wei","doi":"10.1080/09546634.2025.2462783","DOIUrl":null,"url":null,"abstract":"Purpose: Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there is a scarcity of evidence-based guidelines for the management of patients with advanced or metastatic BCC, particularly those who develop resistance to HHI therapy.Materials and methods: We report the case of a patient with advanced BCC of the head and neck, which originated from a nevus sebaceous.Results: The patient initially responded well to sonidegib, an HHI, but resistance emerged within a month. We then modified the systemic therapy to include a combination of radiotherapy and the anti-PD-1 agent sintilimab.Conclusions: This adjusted treatment regimen led to effective long-term clinical responses without significant adverse events.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2462783"},"PeriodicalIF":3.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2462783","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there is a scarcity of evidence-based guidelines for the management of patients with advanced or metastatic BCC, particularly those who develop resistance to HHI therapy.

Materials and methods: We report the case of a patient with advanced BCC of the head and neck, which originated from a nevus sebaceous.

Results: The patient initially responded well to sonidegib, an HHI, but resistance emerged within a month. We then modified the systemic therapy to include a combination of radiotherapy and the anti-PD-1 agent sintilimab.

Conclusions: This adjusted treatment regimen led to effective long-term clinical responses without significant adverse events.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

刺猬通路抑制剂（HHI）联合放疗和免疫治疗晚期基底细胞癌1例报告

目的：基底细胞癌（BCC）是最常见的皮肤癌之一。大多数基底细胞癌可通过手术切除治疗。对于不适合根治性手术的晚期BCC，放疗联合刺猬通路抑制剂（HHI）是有效的全身治疗选择。然而，对于晚期或转移性BCC患者的管理，特别是对HHI治疗产生耐药性的患者，缺乏循证指南。材料和方法：我们报告一例晚期头颈部基底细胞癌患者，起源于皮脂腺痣。结果：患者最初对一种HHI药物sonidegib反应良好，但在一个月内出现耐药性。然后我们修改了全身治疗，包括放疗和抗pd -1药物辛替单抗的组合。结论：这种调整后的治疗方案导致了有效的长期临床反应，没有明显的不良事件。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

The Journal of dermatological treatment

自引率

0.00%

发文量